These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37383526)

  • 21. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021.
    Ossato A; Tessari R; Trabucchi C; Zuppini T; Realdon N; Marchesini F
    Eur J Hosp Pharm; 2023 Jul; 30(4):e15. PubMed ID: 34315774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA COVID-19 Vaccine Reactogenicity among Healthcare Workers: Results from an Active Survey in a Pediatric Hospital from Bucharest, January-February 2021.
    Crăciun MD; Nițescu GV; Golumbeanu M; Tănase AA; Pițigoi D; Săndulescu O; Crăciun P; Enciu BG; Bălănescu RN; Ulici A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.
    Al-Obaydi S; Hennrikus E; Mohammad N; Lehman EB; Thakur A; Al-Shaikhly T
    PLoS One; 2022; 17(8):e0272691. PubMed ID: 35930586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Ahmadizar F; Luxi N; Raethke M; Schmikli S; Riefolo F; Saraswati PW; Bucsa C; Osman A; Liddiard M; Maques FB; Petrelli G; Sonderlichová S; Thurin NH; Villalobos F; Trifirò G; Sturkenboom M;
    Drug Saf; 2023 Jun; 46(6):575-585. PubMed ID: 37103643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-vaccination Adverse Reactions After Receiving the Pfizer-BioNTech Coronavirus Disease 2019 Vaccines Among Healthcare Workers in Sapporo, Japan.
    Shimamura Y; Anbo Y; Furuta Y
    Cureus; 2022 Mar; 14(3):e23549. PubMed ID: 35494967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Raethke M; van Hunsel F; Thurin NH; Dureau-Pournin C; Mentzer D; Kovačić B; Mirošević Skvrce N; De Clercq E; Sabbe M; Trifirò G; Luxi N; Giovanazzi A; Shakir S; Klungel OH; Schmikli S; Sturkenboom M
    Drug Saf; 2023 Apr; 46(4):391-404. PubMed ID: 37024736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Santi Laurini G; Montanaro N; Broccoli M; Bonaldo G; Motola D
    Vaccine; 2023 May; 41(18):2879-2886. PubMed ID: 37024412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites.
    Abbattista M; Martinelli I; Peyvandi F
    J Thromb Haemost; 2021 Oct; 19(10):2554-2558. PubMed ID: 34375510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience.
    Sauserienė J; Liseckienė I; Neverauskė V; Šepetauskienė E; Serapinas D; Mačinskas Š; Šitkauskienė B; Bajoriūnienė I; Vaičiūnienė R; Valius L
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334616
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
    Johnston MS; Galan A; Watsky KL; Little AJ
    JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactogenicity to COVID-19 vaccination in the United States of America.
    Sanyaolu A; Marinkovic A; Prakash S; Desai P; Haider N; Abbasi AF; Mehraban N; Jain I; Ekeh A; Shazley O; Okorie C; Orish VN
    Clin Exp Vaccine Res; 2022 Jan; 11(1):104-115. PubMed ID: 35223671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe.
    Dziedzic A; Riad A; Attia S; Klugar M; Tanasiewicz M
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.